Crinetics Pharmaceuticals Inc annual operating income for fiscal TTM was -$549 million, a decrease of 6.2% from -$517 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($549M) | ($517M) | ($339M) | ($223M) | ($168M) | ($108M) | ($75M) | ($54M) | ($29M) | ($9M) | ($6M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($132M) | ($140M) | ($134M) | ($143M) | ($129M) | ($111M) | ($95M) | ($88M) | ($83M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More CRNX metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All CRNX financial statements → Interactive CRNX charts →
About TickerBase · Data methodology & sources · Privacy · Terms